SHYNDEC(SH:600420) Shang Hai Zheng Quan Bao·2025-11-03 20:28Core Viewpoint - Shanghai Modern Pharmaceutical Co., Ltd. has signed a drug listing license transfer agreement with Anhui Meilai Pharmaceutical Co., Ltd. for the product Lactulose Oral Solution, which will enhance the company's product pipeline and market competitiveness [2][4][14]. Group 1: Transaction Overview - The agreement involves the transfer of the listing license for Lactulose Oral Solution (15ml:10g) from Anhui Meilai to the company's subsidiary, Guoyao Group Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd., for a total transfer fee of RMB 5.86 million [4][10]. - The transaction does not require approval from the company's board or shareholders and is not classified as a related party transaction [4][14]. Group 2: Parties Involved - Anhui Meilai Pharmaceutical Co., Ltd. is a non-listed company with a registered capital of RMB 25.37 million, established on December 30, 2021, and has no related party relationship with the company or its subsidiary [5][6]. - Guoyao Group Zhijun (Shenzhen) Pingshan Pharmaceutical Co., Ltd. is a limited liability company with a registered capital of RMB 50 million, established on July 13, 1990, and is involved in various pharmaceutical and medical services [8]. Group 3: Product Information - Lactulose is an osmotic laxative used for treating chronic functional constipation and has prebiotic effects, helping to balance gut microbiota [9]. - The projected sales for Lactulose Oral Solution in public medical institutions and retail markets in 2024 are estimated at RMB 2.069 billion [9]. Group 4: Agreement Details - The agreement grants the buyer all rights and interests related to the product, including global operational rights and intellectual property rights, with no third-party restrictions [10][11]. - The total transfer fee is RMB 5.86 million, payable in installments based on contract performance milestones [12].